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Background: First-generation integrase strand-transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir
(EVG), have been clinically proven to be effective antiretrovirals for the treatment of HIV-positive patients. However,
their relatively low genetic barrier for resistance makes them susceptible to the emergence of drug resistance
mutations. In contrast, dolutegravir (DTG) is a newer INSTI that appears to have a high genetic barrier to resistance
in vivo. However, the emergence of the resistance mutation R263K followed by the polymorphic substitution M50I
has been observed in cell culture. The M50I polymorphism is also observed in 10-25% of INSTI-naïve patients and
has been reported in combination with R263K in a patient failing treatment with RAL.
Results: Using biochemical cell-free strand-transfer assays and resistance assays in TZM-bl cells, we demonstrate
that the M50I polymorphism in combination with R263K increases resistance to DTG in tissue culture and in
biochemical assays but does not restore the viral fitness cost associated with the R263K mutation.
Conclusions: Since the combination of the R263K mutation and the M50I polymorphism results in a virus with
decreased viral fitness and limited cross-resistance, the R263K resistance pathway may represent an evolutionary
dead-end. Although this hypothesis has not yet been proven, it may be more advantageous to treat HIV-positive
individuals with DTG in first-line than in second or third-line therapy.
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The development of effective antiretrovirals against HIV
has led to significant improvements in longevity and qual-
ity of life for HIV-infected patients. Despite the progress
made in the past 30 years, however, significant issues with
HIV treatment remain including those related to drug re-
sistance, tolerability, ease of dosing, and adherence to ther-
apy [1]. Consequently, new targets for HIV are required to
overcome problems associated with current antiretroviral* Correspondence: mark.wainberg@mcgill.ca
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stated.(ARV) drug classes. The most recently developed drug
class is integrase-strand transfer inhibitors (INSTIs) that
inhibit the previously untargeted HIV-1 integrase enzyme
[2,3]. HIV-1 integrase (IN) is a protein comprising 288
amino acids structured into three domains, i.e. the N-
terminal domain, the catalytic core domain and the C-
terminal domain [4]. These domains are critical for the
proper function of HIV-1 integrase, which is to catalyze
the insertion of the proviral DNA into the host chromo-
some. This process is achieved by two reactions. The first
reaction, referred to as 3′ processing, is defined as the
cleavage of a GT dinucleotide at the 3′ ends of the viral
DNA resulting in the exposure of reactive hydroxyl groups
[5]. These 3′ hydroxyl groups then serve to covalently link
the processed viral DNA and the host DNA in a reactiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication











Figure 1 Occurrence of the M50I polymorphism in treatment-
naïve individuals living with HIV-1 subtype B. Sequence analysis
of subtype B integrase of 2,253 clinical isolates from treatment-naïve
patients from the Stanford HIV Drug Resistance Database for the
following polymorphisms: M50M, M50I, M50T, M50L and M50R.
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petitively inhibited by INSTIs.
INSTIs that are currently available include raltegravir
(RAL), elvitegravir (EVG), and dolutegravir (DTG). These
antiretrovirals are considered effective, minimally toxic,
and tolerable and are now recommended for the treat-
ment of newly diagnosed individuals living with HIV by
the U.S. Department of Health and Human Services. All
of these drugs have demonstrated non-inferiority to efavir-
enz (EFV)-based regimens with respect to viral suppres-
sion [6-10]. In addition, the SAILING study demonstrated
that DTG was superior to RAL at week 48 in patients in-
fected with viruses resistant to two or more non-INSTI
antiretroviral drug classes [11], suggesting a possible use
for DTG in INSTI-naïve treatment-experienced individ-
uals. RAL and EVG possess a modest genetic barrier to re-
sistance which threatens the long-term use and efficacy of
these INSTIs in patients with poor adherence to therapy.
In particular, mutational pathways associated with muta-
tions at positions Y143, N155, and Q148 are associated
with resistance to both RAL and EVG [12,13]. Mutations
at position Q148 also reduce HIV susceptibility to the
more recent INSTI DTG when Q148 substitutions are
associated with several secondary mutations [14,15]. This
newly approved INSTI [16] possesses a greater barrier to
resistance and no major resistance mutation has yet been
identified in treatment-naïve patients treated with DTG
[10,15,17]. However, the R263K mutation has been found
in INSTI-naïve ART-experienced patients receiving DTG
treatment who have failed therapy with this drug [18]. As
such, tissue culture selection studies with this drug have
revealed the emergence of the R263K mutation in the
integrase of HIV subtypes B and circulating recombinant
form CRF02_A/G viruses [19]. R263K has been shown to
confer low levels of resistance to DTG while decreasing
viral fitness [19]. The same selection study also revealed
multiple secondary mutations including the M50I poly-
morphism in subtype B integrase [19].
In previous studies, the M50I polymorphism has been
found in 10-25% of INSTI-naïve patients [20]. In addition,
this polymorphism has been observed in combination
with R263K in a patient who subsequently failed treatment
with RAL [21]. As a result, it is reasonable to speculate
that the presence of M50I could compromise DTG ac-
tivity in INSTI-naïve patients as well as contribute to
cross-resistance in treatment-experienced patients. Here,
we present the biochemical characterization of the M50I
substitution alone and in combination with the primary
resistance mutation R263K in subtype B integrase. We in-
vestigated the effect of these mutations on strand-transfer
activity, viral fitness and resistance to INSTIs DTG,
RAL, and EVG. Our results demonstrate that the M50I
polymorphism does not restore the loss in HIV-1 in-
fectivity associated with R263K and confers moderateresistance to DTG when combined with the latter re-
sistance mutation.Results
Occurrence of the M50I polymorphism in treatment-naïve
individuals living with HIV-1 subtype B
The M50I polymorphism was selected in culture as a sec-
ondary mutation to R263K [19] as well as sequenced from
a patient failing treatment with RAL [21]. As a result, we
wanted to determine the frequency with which the M50I
polymorphism occurs in the INSTI-naïve patient popula-
tion. Analysis of clinical isolates of INSTI-naïve patients
from the Stanford HIV Drug Resistance Database revealed
that the M50I polymorphism was present at a frequency
of 10% in subtype B integrase (Figure 1). The wild-type
M50 was the most common genotype with a frequency of
87% suggesting that integrase subtype B is not highly vari-
able at this position.
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strand-transfer activity
Previous studies have demonstrated that the primary resist-
ance mutation R263K decreases integrase activity in cell-
free assays [19]. Here, with the use of wild-type and mutant
integrase proteins, we show that M50I does not compen-
sate for the decrease in enzymatic activity associated with
R263K. When varying the concentration of the INBWT,
INBM50I, INBR263K, and INBM50I/R263K proteins (Figure 2A),
the activity of the M50I mutant initially appeared to be
greater than that of the WT enzyme (Figure 2B). However,
further investigation revealed that the Vmax/1/2MaxProt
values of the M50I and R263K enzymes were decreased
compared to WT (Figures 2C-D). The addition of M50I to
R263K did not compensate for the decreased Vmax/1/2Max-
Prot of the R263K enzyme (Figure 2D). The results were
similar when we varied the concentration of target DNA
(Figure 3). In these experiments, both the Vmax and Km of
the M50I enzyme were comparable to those of the WT en-
zyme whereas R263K resulted in a decreased Vmax and in-
creased Km (Figures 3B-D). The addition of M50I to R263K
slightly increased integrase Vmax but further increased theA  
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Figure 2 Addition of M50I to R263K does not increase integrase stran
wild-type and mutant enzymes. A) Relative strand-transfer activity when va
D) Enzyme efficiency as determined by the division of Vmax by 1/2MaxProt.Km, resulting in a non-significant increase in enzyme effi-
ciency (Figure 3D). Overall, the addition of M50I to R263K
did not compensate for the decrease in enzymatic efficiency
associated with the R263K mutant.
The effect of M50I with R263K on susceptibility to INSTIs
The integrase coding region of HIV-1 contains similar
levels of natural variation as that seen in protease [22]. Fur-
thermore, the pre-existing polymorphism L63P which
emerges during treatment with PIs has been shown to be
compensatory when combined with a primary resistance
mutation [22]. We therefore wanted to determine if the
addition of M50I, a natural polymorphism in integrase, to
R263K affected susceptibility to DTG, RAL, and EVG in
strand-transfer assays. Analysis with the competitive inhib-
ition model was used to generate values of relative Vmax
and Ki expressed in fold-change (FC) (Table 1). The R263K
mutation did not greatly affect DTG activity (FC = 2.6) and
the addition of M50I did not have a significant effect on
the level of resistance observed (FC = 2.8). In contrast,
the addition of M50I to R263K decreased susceptibility
to EVG (FC = 6.4 for M50I/R263K compared to 3.0 forB
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d-transfer activity. Strand-transfer activity and Vmax/1/2MaxProt of
rying protein concentration. B) Vmax values. C) 1/2MaxProt values.
Error bars represent the standard errors of the means (SEM).
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Figure 3 The effect of M50I with R263K on enzyme activity. Strand-transfer activity and enzyme efficiency of wild-type and mutant enzymes.
A) Relative strand-transfer activity when varying the concentration of biotinylated target DNA. B) Vmax values. C) Km values. D) Enzyme efficiency
as determined by the division of Vmax by Km. Error bars represent the standard errors of the means (SEM).
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M50I mutant enzyme was associated with low-level resist-
ance to all INSTIs tested (FC ~ 2.5) in these cell-free assays.
Using TZM-bl assays with pNL4.3 M50I and R263K vi-
ruses, we also showed that the combination of M50I and
R263K increased resistance to DTG (FC = 15.6 fold) com-
pared to R263K alone (FC = 8.5 fold) (Table 2). When
these experiments were repeated with EVG, the R263K
mutation alone conferred moderate-level resistance (FC =
21.4 fold) and, when combined with M50I, resistance to
EVG was further increased (FC = 34.4 fold). In contrast,
the M50I/R263K double mutant conferred only low-level
resistance to RAL (FC = 3.6 fold). M50I alone did notTable 1 Effects of the M50I and R263K mutations on DTG, RA
DTG
INB Relative Fold Relati
Vmax Change (Ki) Vmax
WT 100 1 100
M50I 109 2.085 118
R263K 105 2.627 106
M50I/R263K 108 2.824 95confer resistance to DTG or RAL but did confer low-level
resistance to EVG (FC = 5.4 fold).
M50I does not compensate for the reduction in HIV
replication associated with R263K
To determine whether M50I might impact viral replica-
tion capacity, we performed TZM-bl infection assays
with varying amounts of wild-type pNL4.3, pNL4.3INB
(R263K), and pNL4.3INB(M50I/R263K) viruses (Figure 4). As
previously demonstrated [19,23] and confirmed here, the
R263K single mutation modestly diminished HIV infect-
ivity whilst the addition of M50I to R263K further in-
creased this deficit (Figure 4A). Long-term infectionL, and EVG inhibitory constants (Ki)
RAL EVG
ve Fold Relative Fold





Table 2 Effects of the M50I and R263K mutations on IC50s for DTG, RAL, and EVG
DTG RAL EVG
Backbone Genotype IC50 (nM) FC IC50 (nM) FC IC50 (nM) FC
pNL4.3 WT 0.3113 - 0.1023 - 1.082 -
M50I 0.6053 1.94 0.04851 0.47 5.9 5.45
R263K 2.662 8.55 0.1898 1.85 23.16 21.4
M50I/R263K 4.854 15.59 0.3643 3.56 37.26 34.44
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lication deficit was mostly observed early in the infection
course (Figure 4B). The M50I mutant alone did not
negatively impact HIV replication capacity; however, the
addition of M50I to R263K further decreased viral fit-
ness. Combined with our biochemical results, these data
indicate that the M50I mutation does not compensate
for the loss in replication fitness conferred by R263K.
Discussion
M50I is an accessory mutation that was selected in tissue
culture subsequent to the emergence of R263K under
DTG pressure [23]. Furthermore, this natural polymorph-
ism has been detected in clinical isolates [21] and can be
found in 10-25% of INSTI treatment-naïve patients [20].
Primary mutations, such as R263K, can often negatively
impact integrase enzymatic activity and lower viral replica-
tion capacity [24]. Secondary mutations therefore compen-
sate for this by increasing levels of drug resistance while
simultaneously restoring viral fitness [24]. Here, we pro-
vide evidence that M50I alone does not negatively impact
integrase strand-transfer activity and HIV replication cap-
acity, an observation that explains the existence of this
polymorphic substitution in untreated patients.
In addition to M50I, other secondary mutations have
emerged in the presence of R263K in tissue culture expe-
riments with DTG, i.e. E138K and H51Y [19]. This latterA  B




























Figure 4 M50I does not compensate for the reduction in HIV replicat
on HIV infectivity in TZM-bl cells (A) and replication capacity in PM1 cells (mutation has previously been characterized [23]. Compar-
able to H51Y, the addition of M50I to R263K increased
resistance against DTG (15.6-fold for M50I/R263K versus
16.5-fold for H51Y/R263K). Furthermore, both of the
H51Y and M50I mutations were innocuous when tested in
the absence of R263K. In contrast, the addition of H51Y to
R263K was very detrimental to integrase strand-transfer
activity [23]. Although the combination of M50I/R263K
did not restore enzyme efficiency (Figure 3D), the M50I
polymorphism partially restored integrase maximal activ-
ity to 92% of the WT Vmax for M50I/R263K (Figure 3B),
as compared to approximately 20% for H51Y/R263K [21].
Since the M50I/R263K double mutant decreased integrase
affinity for DNA compared to R263K alone (Figure 3C),
an effect also observed with H51Y [23], this combination
of mutations did not restore integration. In agreement
with these results, the addition of M50I to R263K did not
restore viral infectivity and replication capacity, similar to
what has been reported for H51Y/R263K [23]. These re-
sults are in accordance with previous results regarding
polymorphisms and their role in conferring drug resist-
ance, i.e. patient-derived viruses with polymorphisms do
not demonstrate a decrease in susceptibility to INSTIs un-
less a primary resistance mutation is also present [22,25].
Although innocuous for RAL and DTG, the presence
of M50I may slightly decrease HIV-1 susceptibility to
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ion associated with R263K. Effects of the M50I and R263K mutations
B).
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gated whether M50I is over-represented in patients who
have failed EVG-based therapy in clinical trials [8,26-28].
Overall, M50I by itself is unlikely to lead to treatment
failure. Besides its effect on susceptibility to EVG, the
biochemical characterization of the M50I integrase en-
zyme demonstrates that this polymorphism alone does
not affect strand-transfer activity. This observation is in
agreement with the natural prevalence of this substitu-
tion since integration is essential to HIV-1 infectivity.
When associated with the R263K mutation, M50I dem-
onstrates a tendency toward improving maximal strand-
transfer activity while decreasing integrase affinity for
target DNA, as measured by Vmax and Km values, re-
spectively (Figure 3). This strongly suggests that M50I is
unable to compensate for the R263K defect in DNA
binding that has been previously reported [19].
Conclusion
The addition of M50I to R263K fails to restore the def-
icit in HIV replication capacity conferred by R263K. This
observation is in agreement with the hypothesis that the
R263K resistance pathway may represent an evolutionary
dead-end for HIV-1; however this hypothesis requires
further evaluation and remains to be proven. These re-
sults also help to explain the absence of de novo resist-
ance mutations in treatment-naïve patients who have
been treated with DTG in clinical trials.
Methods
Cells and antiviral compounds
Infectivity experiments were performed using TZM-bl
cells and 293T cells for purposes of transfection with
replication-competent wild-type or mutant HIV-1. TZM-
bl cells were obtained from the NIH AIDS Research Re-
agent Program. The 293T cell line was obtained from the
American Type Culture Collection (CRL-11268). Both cell
lines were subcultured every 3–4 days in Dulbecco’s min-
imal essential medium (DMEM) and kept at 37°C under
5% CO2. DTG, RAL, and EVG were provided by GlaxoS-
mithKline/ViiV Healthcare, Merck Inc, and Gilead Sci-
ences, respectively.
Protein expression and purification
Wild-type and mutant subtype B integrase proteins were
expressed using Escherichia coli BL21 (DE3) Gold cells, F_
ompT hsdSB(rB_ mB_) dcm gal _(DE3)(Stratagene). Bacter-
ial cultures were grown at 37°C in 500 ml Luria-Bertani
(LB) broth supplemented with 100 μg/ml ampicillin until
they reached an optical density of 0.4-0.6 at 600 nm. Protein
expression was induced with 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG) for 3 hr at 37°C, 200 rpm. The
cultures were then centrifuged at 7,000 rpm for 10 min.
The cell pellets were stored at −80°C. The purification ofintegrase recombinant proteins was performed as previ-
ously described for His-tagged integrase [19,29].
Integrase strand-transfer activity
The strand-transfer activity of the wild-type, M50I, R263K,
and M50I/R263K integrase subtype B proteins were mea-
sured using a microtiter plate assay as previously described
[19]. Briefly, equimolar amounts of donor DNA LTR sense,
5′AmMC12ACCCTTTTAGTCAGTGTGGAAAATCTC
TAGCAGT-3′, and antisense, 5′-ACTGCTAGAGATTTT
CCACACTGACTAAAAG-3′, were annealed by heating
for 10 min at 95°C. Once cooled, the DNA LTR functional
duplexes were covalently linked to Costar DNA-Bind 96-
well plates (Corning) and stored at 4°C. After 48 hr, the
plates were blocked and washed as previously described
[19]. The wild-type and mutant integrase proteins were di-
luted to a final concentration of 400 nM and incubated on
the plates at room temperature for 30 min. Next, the indi-
cated concentrations of INSTIs were either added or not,
followed by the addition of the biotinylated target DNA du-
plex (sense 5′-TGACCAAGGGCTAATTCACT-3Bio, and
antisense (D), 5′-AGTGAATTAGCCCTTGGTCA-3Bio).
Following incubation for 1 hr at 37°C, the plates were
washed twice and quantified with Eu-labelled Streptavidin
(PerkinElmer) as previously described [19].
Generation of replication-competent HIV-1
The pNL4.3INB(R263K) plasmid has been described previ-
ously [19]. The pNL4.3INB(M50I) and pNL4.3INB(M50I/R263K)
replication-competent HIV-1 plasmids were generated
using the QuickChange II XL Site-Directed mutagenesis
kit. The primers used for the M50I mutation were: sense,
5′-CTAAAAGGGGAAGCCATACATGGACAAGTAGAC
TG-3′ and antisense, 5′-CAGTCTACTTGTCCATGTAT
GGCTTCCCCTTTTAG-3′. Following mutagenesis, the
plasmids were digested with Dpn1 for 4 hr at 37°C and
transformed using Escherichia coli strain XL10-Gold ultra-
competent cells, Tetr _(mcrA)183 _(mcrCB-hsdSMR-mrr)
173endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F =
proAB lacIqZ_M15Tn10 (Tetr) Amy Camr] (Stratagene).
The QIAprep MiniPrep Kit (QIAGEN) was used for plas-
mid purification and the plasmids were quantified with
NanoDrop. Presence of the mutations was confirmed by
sequencing. Genetically homogenous HIV-1 viruses were
produced by transfecting 12.5 μg of wild-type or mutant
pNL4.3 plasmids into 293T cells as previously described
[19]. An enzyme-linked immunosorbent assay (ELISA)
(ABL, Inc.) was used to measure levels of p24 in culture.
Reverse Transcriptase (RT) activity was measured as previ-
ously described [30].
Resistance assays in TZM-bl cells
HIV susceptibility to DTG, RAL, and EVG was deter-
mined using short-term resistance assays with TZM-bl
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well were infected with the WT, M50I, R263K, or M50I/
R263K viruses in the presence of serial dilutions of DTG,
RAL, or EVG in 96-well plates (Corning). The amount of
virus added to each well was normalized using results
from RT activity. After incubation for 48 hr at 37°C and
5% CO2, luciferase activity was measured using the lucifer-
ase assay system (Promega) and a Micro-Beta2 lumin-
ometer (PerkinElmer).
HIV infectivity and replication capacity
Non-competitive short-term infectivity assays in TZM-bl
cells were used to evaluate HIV infectivity as previously
described [19]. Long-term infection assays were used to
determine HIV replication capacity in PM1 cells by quan-
tifying RT activity (cpm) as previously described [23,30].
Data analysis
Unless otherwise indicated, all experiments consisted of at
least 2 sets of experiments performed in triplicates, yielding
6 independent values for each data point. For each experi-
ment, strand-transfer values in the absence of drug were
arbitrarily determined as 100%. When varying concentra-
tions of target DNA and protein were employed, strand-
transfer results were fit to the Michaelis-Menten equation
with the use of GraphPad Prism 5.0 software to generate
values for Vmax, Km and Ki. The half-maximal protein con-
centration, defined as ½ of the calculated concentration at
which maximal activity is reached, was determined at vary-
ing INB concentrations. Enzyme performance was deter-
mined by dividing Vmax by Km as previously described [31].
The strand-transfer activity of the wild-type and mutant
enzymes in the presence of INSTIs was determined using
the competitive inhibition model and by constraining to
Km values based on the delta target DNA results. The Km
values for the INBWT, INBM50I, INBR263K, INBM50I/R263K
enzymes were 3.745, 8.997, 11.40 and 9.660, respectively.
Using replication capacity experiments in TZM-bl cells in
the presence of DTG, RAL or EVG, fifty percent inhibitory
concentrations (IC50s) were determined for the wild-type
and mutant viruses using the sigmoid dose–response func-
tion of the same software.
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